Clinical Trials

9 enrolled

Lymphoma, B-Cell

NCT07569965 2026-05-06

FRONTIER

52 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06970496 2026-05-05

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

48 enrolled

Recurrence, Lymphoma, B-Cell

NCT07563543 2026-05-04

RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

10 enrolled

Lymphoma, B-Cell

NCT07546630 2026-04-29

Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma

Lymphoma, B-Cell

NCT07539688 2026-04-20

Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma

18 enrolled

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07532525 2026-04-16

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Burkitt Lymphoma, Lymphoma, B-Cell

NCT07520006 2026-04-13

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

150 enrolled

Phase 3 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07516093 2026-04-08

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

620 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07506668 2026-04-02

RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

10 enrolled

Lymphoma, B-Cell

NCT07502872 2026-03-31

TPG

30 enrolled

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07477366 2026-03-17

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Lymphoma, B-Cell

NCT07439653 2026-02-27

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

155 enrolled

Lymphoma, B-Cell

NCT07385612 2026-02-04

REFRACT-LyMA

80 enrolled

Lymphoma, B-Cell

NCT07367685 2026-01-26

Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

6 enrolled

Phase NA Not yet recruiting

Lymphoma, B-Cell

NCT07345741 2026-01-16

Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

28 enrolled

Recurrence, Lymphoma, B-Cell

NCT07334574 2026-01-13

XP-006

Lymphoma, B-Cell

NCT07335328 2026-01-13

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

24 enrolled

Lymphoma, B-Cell

NCT07316920 2026-01-06

A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

19 enrolled

Recurrence, Lymphoma, B-Cell

NCT07166549 2025-12-24

BaseCAR-01

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07234045 2025-11-18

A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

30 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

15 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07198373 2025-09-30

Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma

40 enrolled

Lymphoma, B-Cell

NCT07168291 2025-09-17

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

3 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07162571 2025-09-09

MSTH-CAR002

17 enrolled

Lymphoma, B-Cell

NCT05779930 2025-08-15

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07068906 2025-07-16

A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

27 enrolled

Lymphoma, B-Cell

NCT04419909 2025-07-02

Retreatment With CTL019/CTL119

Lymphoma, B-Cell

NCT07048353 2025-07-02

CAR-T，MTD

15 enrolled

Lymphoma, Lymphoma, B-Cell

NCT07032324 2025-06-23

CT1190B

27 enrolled

Lymphoma, B-Cell

NCT07024147 2025-06-17

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Phase 4 Not yet recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06956092 2025-05-02

Glofitamab

40 enrolled

Lymphoma, B-Cell

NCT06894693 2025-03-25

A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

13 enrolled

Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06847529 2025-03-12

Systemic Inflammatory Markers in B-cell Neoplasm

70 enrolled

Lymphoma, B-Cell

NCT06721598 2024-12-06

An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders

60 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06646666 2024-11-01

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

35 enrolled

Lymphoma, B-Cell

NCT06573099 2024-08-27

A Real-World Study on Extranodal Lymphoma

5,000 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06314828 2024-03-18

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

30 enrolled

Lymphoma, B-Cell

NCT06142188 2023-11-21

Relmacabtagene Autoleucel in Hematologic Malignancies

150 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell

NCT06062641 2023-11-07

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

50 enrolled

Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05968001 2023-08-01

Obinutuzumab in Chinese Real-world Patients With iNHL

400 enrolled

Lymphoma, B-Cell

NCT05834426 2023-06-22

Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

50 enrolled

Phase 4 Not yet recruiting

Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05814848 2023-06-15

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

13 enrolled

Recurrence, Lymphoma, B-Cell

NCT05091541 2021-10-25

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

125 enrolled